Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shoko Takano

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Journal of Hepato-Biliary-Pancreatic Sciences|December 15, 2021
Safety and response after peptide receptor radionuclide therapy with <sup>177</sup> Lu-DOTATATE for neuroendocrine tumors in phase 1/2 prospective Japanese trialAtsushi Kudo, Ukihide Tateishi, Ryoichi Yoshimura, et al.
Medicine|August 3, 2019
Outcome of postoperative radiation therapy for cholangiocarcinoma and analysis of dose-volume histogram of remnant liverYuki Mukai, Ryusei Matsuyama, Izumi Koike, et al.
Digestion|June 14, 2017
Clinical Usefulness of Somatostatin Receptor Scintigraphy in Japanese Patients with Gastroenteropancreatic Neuroendocrine TumorsSho Hasegawa, Noritoshi Kobayashi, Motohiko Tokuhisa, et al.
International Journal of Clinical Oncology|September 30, 2025
Policy recommendations for promoting nuclear medicine therapy in Japan 2025, from the Working Group for promoting nuclear medicine therapy of the Japan Society of Clinical OncologyKotaro Suzuki, Hideaki Miyake, Anri Inaki, et al.
Annals of Nuclear Medicine|September 17, 2021
Safety and efficacy of peptide receptor radionuclide therapy with <sup>177</sup>Lu-DOTA<sup>0</sup>-Tyr<sup>3</sup>-octreotate in combination with amino acid solution infusion in Japanese patients with somatostatin receptor-positive, progressive neuroendocrine tumorsNoritoshi Kobayashi, Shoko Takano, Kenichi Ito, et al.
International Journal of Clinical Oncology|January 8, 2026
Correction to: Policy recommendations for promoting nuclear medicine therapy in Japan 2025, from the Working Group for promoting nuclear medicine therapy of the Japan Society of Clinical OncologyKotaro Suzuki, Hideaki Miyake, Anri Inaki, et al.
World Journal of Urology|December 26, 2019
Outcomes of treatment for localized prostate cancer in a single institution: comparison of radical prostatectomy and radiation therapy by propensity score matching analysisNarihiko Hayashi, Kimito Osaka, Kentaro Muraoka, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Journal of Hepato-Biliary-Pancreatic Sciences|December 15, 2021
Safety and response after peptide receptor radionuclide therapy with <sup>177</sup> Lu-DOTATATE for neuroendocrine tumors in phase 1/2 prospective Japanese trialAtsushi Kudo, Ukihide Tateishi, Ryoichi Yoshimura, et al.
Medicine|August 3, 2019
Outcome of postoperative radiation therapy for cholangiocarcinoma and analysis of dose-volume histogram of remnant liverYuki Mukai, Ryusei Matsuyama, Izumi Koike, et al.
Digestion|June 14, 2017
Clinical Usefulness of Somatostatin Receptor Scintigraphy in Japanese Patients with Gastroenteropancreatic Neuroendocrine TumorsSho Hasegawa, Noritoshi Kobayashi, Motohiko Tokuhisa, et al.
International Journal of Clinical Oncology|September 30, 2025
Policy recommendations for promoting nuclear medicine therapy in Japan 2025, from the Working Group for promoting nuclear medicine therapy of the Japan Society of Clinical OncologyKotaro Suzuki, Hideaki Miyake, Anri Inaki, et al.
Annals of Nuclear Medicine|September 17, 2021
Safety and efficacy of peptide receptor radionuclide therapy with <sup>177</sup>Lu-DOTA<sup>0</sup>-Tyr<sup>3</sup>-octreotate in combination with amino acid solution infusion in Japanese patients with somatostatin receptor-positive, progressive neuroendocrine tumorsNoritoshi Kobayashi, Shoko Takano, Kenichi Ito, et al.
International Journal of Clinical Oncology|January 8, 2026
Correction to: Policy recommendations for promoting nuclear medicine therapy in Japan 2025, from the Working Group for promoting nuclear medicine therapy of the Japan Society of Clinical OncologyKotaro Suzuki, Hideaki Miyake, Anri Inaki, et al.
World Journal of Urology|December 26, 2019
Outcomes of treatment for localized prostate cancer in a single institution: comparison of radical prostatectomy and radiation therapy by propensity score matching analysisNarihiko Hayashi, Kimito Osaka, Kentaro Muraoka, et al.
Pageof 3